16 recruiting, 8 not yet recruiting, 5 unknown, 3 active not recruiting. 21 Phase 2, 11 Phase 3, 6 Phase 1, 1 Not applicable, 1 Phase 4.
Follow Carboplatin injection: new trials by email Literature Review of Carboplatin injection trials Research Report on Carboplatin injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 436 | 2026-12-01 | 2026-10-26 |
| A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC LBL-024 for Injection, Etoposide injection, Cisplatin injection - Advanced Extrapulmonary Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Nanjing Leads Biolabs Co.,Ltd | 280 | 2026-11-16 | 2026-10-19 |
| HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer HB0025 Injection, Paclitaxel injection, Carboplatin injection - First-line pMMR Endometrial Cancer | Phase 3 | Recruiting | Shanghai Huaota Biopharmaceutical Co., Ltd. | 333 | 2026-10-20 | 2026-10-29 |
| Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. ALK202 for injection, Osimertinib Mesylate Tablets, Ivonescimab Injection - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Not yet recruiting | Shanghai Allink Biotherapeutics Co., Ltd. | 252 | 2026-06-30 | 2026-05-22 |
| A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer BEBT-209 capsules, Carboplatin Injection, Gemcitabine Hydrochloride for Injection - Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer | Phase 2 / Phase 3 | Recruiting | BeBetter Med Inc | 446 | 2026-06-04 | 2026-08-18 |
| SKB500 Combinations in Patients With Small Cell Lung Cancer SKB500 Powder for Injection, KL-A167 Injection, Carboplatin Injection - Small Cell Lung Cancer | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 80 | 2026-01-30 | 2026-05-08 |
| Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer Carboplatin Injection, Paclitaxel Injection - Squamous Non-small Cell Lung Cancer | Phase 3 | Not yet recruiting | Shanghai Huaota Biopharmaceutical Co., Ltd. | 480 | 2026-01-15 | 2026-01-22 |
| Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer Pemetrexed injection, Carboplatin Injection, Cisplatin injection - Non Squamous Non-small Cell Lung Cancer | Phase 3 | Not yet recruiting | Shanghai Huaota Biopharmaceutical Co., Ltd. | 500 | 2026-01-15 | 2026-02-03 |
| A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors SHR-7787 Injection, SHR-1316 Injection, SHR-4849 Injection - Malignant Solid Tumors | Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 400 | 2025-12-23 | 2026-01-12 |
| A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer SHR-1316 Injection, Cisplatin Injection, Carboplatin Injection - Advanced Cervical Cancer | Phase 3 | Recruiting | Shanghai Shengdi Pharmaceutical Co., Ltd | 720 | 2025-10-17 | 2026-04-15 |
| A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer SHR-1316 (sc) Injection, SHR-1316 Injection, Carboplatin Injection - Widespread Small Cell Lung Cancer | Phase 1 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 24 | 2025-06-16 | 2026-06-30 |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] LBL-024 for Injection, Docetaxel Injection, Bevacizumab Injection - Advanced Solid Tumour | Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 250 | 2025-06-11 | 2026-08-27 |
| SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer SHR-A1811, Adebelimab injection, Bevacizumab injection - Recurrent or Metastatic Cervical Cancer | Phase 1 / Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 100 | 2025-04-25 | 2025-06-06 |
| Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC JSKN016, Carboplatin, Furmonertinib Mesylate - Advanced Non-small Cell Lung Cancer | Phase 1 | Recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 288 | 2025-04-02 | 2026-03-30 |
| A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer Apatinib, Adebrelimab, Etoposide Injection - Small Cell Lung Cancer Extensive Stage | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 34 | 2025-01-25 | 2025-01-22 |
| Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ifupinostat Hydrochloride for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | BeBetter Med Inc | 416 | 2025-01-06 | 2026-08-19 |
| Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation Firmonertinib Mesilate Tablets, Pemetrexed Disodium for Injection, Cisplatin for injection - EGFR, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 | Recruiting | Allist Pharmaceuticals, Inc. | 300 | 2024-11-19 | 2026-08-13 |
| Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer Adebrelimab injection, Albumin-Bound Paclitaxel, Carboplatin injection - Resectable Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 42 | 2024-10-01 | 2024-09-19 |
| A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases Furmonertinib Mesilate Tablets, Carboplatin Injection, Cisplatin for injection - NSCLC Patients With Brain Metastasis | Phase 3 | Recruiting | Allist Pharmaceuticals, Inc. | 380 | 2024-09-26 | 2026-08-13 |
| Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations BEBT-109 Capsules, Pemetrexed Disodium for Injection, Carboplatin Injection - Non Small Cell Lung Cancer | Phase 2 | Recruiting | BeBetter Med Inc | 30 | 2024-08-28 | 2026-08-18 |
Showing 20 of 36. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Small Cell Lung Carcinoma (6) · Lymphoma, Large B-Cell, Diffuse (2) · Recurrence (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Neuroendocrine (1) · Endometrial Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Thoracic Neoplasms (1) · Triple Negative Breast Neoplasms (1)
BeBetter Med Inc (5) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3) · Nanjing Leads Biolabs Co.,Ltd (3) · Shanghai Huaota Biopharmaceutical Co., Ltd. (3) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (3) · Allist Pharmaceuticals, Inc. (2) · Shanghai Hengrui Pharmaceutical Co., Ltd. (2) · Sichuan University (2) · Beijing Chest Hospital, Capital Medical University (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Centre Hospitalier Universitaire Dijon (1) · Fujian Cancer Hospital (1) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd (1) · Shanghai Allink Biotherapeutics Co., Ltd. (1) · Shanghai Shengdi Pharmaceutical Co., Ltd (1)
China (32) · France (1)
You Lu, MD (2) · Yuankai Shi, Phd (2) · Caicun Zhou, MD (1) · Dong Wang, PH.D (1) · Dongqing Lv, MD (1) · Juan Li, MD (1) · Li Zhang (1) · Li Zhang, Master (1) · Liang Liu, MD. Ph.D (1) · Lin Shen (1) · Qiang Liu, PhD (1) · Qiang Liu, Phd (1) · Quchang Ouyang, PhD (1) · Quchang Ouyang, Phd (1)